Covered recipient · General Payments record
ROBERT A HAUSER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$324,868.27
271 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $113,379.17 | 36 |
| Honoraria | $101,730.00 | 17 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,934.71 | 35 |
| Travel and Lodging | $40,704.06 | 90 |
| Food and Beverage | $6,120.33 | 93 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amneal Pharmaceuticals LLC | $99,474.02 | 46 |
| Acorda Therapeutics, Inc | $64,502.32 | 37 |
| Neurocrine Biosciences, Inc. | $37,888.98 | 59 |
| Kyowa Kirin, Inc. | $37,093.33 | 28 |
| US WorldMeds, LLC | $23,981.48 | 50 |
| ACADIA Pharmaceuticals Inc | $19,152.89 | 18 |
| H. Lundbeck A S | $17,225.22 | 4 |
| Adamas Pharmaceuticals, Inc. | $10,700.00 | 12 |
| Mitsubishi Tanabe Pharma America, Inc. | $7,231.87 | 2 |
| Teva Pharmaceuticals USA, Inc. | $2,373.95 | 8 |
| JAZZ PHARMACEUTICALS INC. | $2,100.00 | 2 |
| Lundbeck LLC | $1,618.84 | 2 |
| APO-PHARMA INC. | $1,500.00 | 1 |
| Allergan Inc. | $13.69 | 1 |
| AbbVie, Inc. | $11.68 | 1 |
Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT A HAUSER
NPI 1558384743 · CMS profile ID 342421
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1558384743?year=2019&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT A HAUSER, NPI 1558384743, CMS profile ID 342421. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558384743?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ROBERT A HAUSER, NPI 1558384743, CMS profile ID 342421. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558384743?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ROBERT A HAUSER, NPI 1558384743, CMS profile ID 342421, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1558384743?year=2019&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
271 matching records · $324,868.27 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–271 of 271.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | $54.96 | 02/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693134099 | CMS |
| Neurocrine Biosciences, Inc. | $59.42 | 02/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693134101 | CMS |
| Neurocrine Biosciences, Inc. | $4,000.00 | 02/16/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693134103 | CMS |
| Neurocrine Biosciences, Inc. | $380.60 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693134073 | CMS |
| Neurocrine Biosciences, Inc. | $29.17 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693134075 | CMS |
| Neurocrine Biosciences, Inc. | $17.66 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693134079 | CMS |
| Neurocrine Biosciences, Inc. | $125.00 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693134081 | CMS |
| Acorda Therapeutics, Inc | $12.66 | 01/31/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 633494801 | CMS |
| Acorda Therapeutics, Inc | $7.65 | 01/30/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 633494799 | CMS |
| JAZZ PHARMACEUTICALS INC. | $1,500.00 | 01/30/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684155461 | CMS |
| ACADIA Pharmaceuticals Inc | $63.60 | 01/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005343 | CMS |
| ACADIA Pharmaceuticals Inc | $11.57 | 01/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005345 | CMS |
| ACADIA Pharmaceuticals Inc | $93.37 | 01/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005347 | CMS |
| ACADIA Pharmaceuticals Inc | $11.01 | 01/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005349 | CMS |
| ACADIA Pharmaceuticals Inc | $9,500.00 | 01/24/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005331 | CMS |
| ACADIA Pharmaceuticals Inc | $93.37 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005333 | CMS |
| ACADIA Pharmaceuticals Inc | $386.10 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005335 | CMS |
| ACADIA Pharmaceuticals Inc | $58.34 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005337 | CMS |
| ACADIA Pharmaceuticals Inc | $29.77 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005339 | CMS |
| ACADIA Pharmaceuticals Inc | $653.14 | 01/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700005341 | CMS |
| Acorda Therapeutics, Inc | $500.00 | 01/15/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 633494797 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,002.10 | 2 |
| PY2025 | Principal investigator | $1,000,583.03 | 142 |
| PY2024 | Recipient | $1,416.14 | 6 |
| PY2024 | Principal investigator | $1,042,300.41 | 59 |
| PY2023 | Principal investigator | $922,088.00 | 59 |
| PY2022 | Principal investigator | $808,666.23 | 62 |
| PY2021 | Recipient | $374.16 | 1 |
| PY2021 | Principal investigator | $679,214.02 | 62 |
| PY2020 | Recipient | $336.64 | 2 |
| PY2020 | Principal investigator | $533,838.21 | 35 |
| PY2019 | Principal investigator | $1,080,594.13 | 79 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
144 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,656.72 | 12/31/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease | No dispute reported | 06/30/2026 | 1202534217 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,931.00 | 12/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669954 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,924.45 | 12/19/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046944 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $172.80 | 12/19/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046946 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $135.00 | 12/19/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046948 |
| Principal investigator 1 | Roche TCRC, Inc. | $635.50 | 12/18/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669958 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,483.22 | 12/18/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669961 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 12/11/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Open-label Trial in Parkinsons Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202530118 |
| Recipient | Amneal Pharmaceuticals LLC | $3,627.10 | 12/11/2025 | Covered Recipient Physician | IPX203-401-23 | No dispute reported | 06/30/2026 | 1220530670 |
| Recipient | Amneal Pharmaceuticals LLC | $375.00 | 12/11/2025 | Covered Recipient Physician | IPX203-401-23 | No dispute reported | 06/30/2026 | 1220530675 |
| Principal investigator 1 | ABBVIE INC. | $2,160.00 | 12/04/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202527910 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,036.80 | 12/04/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046934 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,685.15 | 12/04/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046936 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,156.00 | 12/04/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046938 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $114.75 | 12/04/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046940 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $515.70 | 12/04/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046942 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,424.66 | 11/26/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046932 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 11/19/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORI | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202524591 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 11/19/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202524626 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 11/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202524395 |
| Principal investigator 1 | Roche TCRC, Inc. | $9,240.30 | 11/13/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669949 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,087.16 | 11/06/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046930 |
| Principal investigator 1 | ABBVIE INC. | $2,160.00 | 11/05/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202521561 |
| Principal investigator 1 | Ipsen Innovation | $2,000.00 | 10/31/2025 | Non-covered Recipient Entity University Of South Florida Health | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184290836 |
| Principal investigator 1 | Ipsen Innovation | $13,865.00 | 10/31/2025 | Non-covered Recipient Entity University Of South Florida Health | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184290838 |
| Principal investigator 1 | Ipsen Innovation | $2,500.00 | 10/31/2025 | Non-covered Recipient Entity University Of South Florida Health | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184290842 |
| Principal investigator 1 | Ipsen Innovation | $2,750.00 | 10/31/2025 | Non-covered Recipient Entity University Of South Florida Health | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184290844 |
| Principal investigator 1 | Genentech, Inc. | $2,374.00 | 10/29/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | No dispute reported | 06/30/2026 | 1211670700 |
| Principal investigator 1 | Ipsen Innovation | $3,300.00 | 10/29/2025 | Non-covered Recipient Entity University Of South Florida Health | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184290840 |
| Principal investigator 1 | Genentech, Inc. | $62,160.00 | 10/23/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | No dispute reported | 06/30/2026 | 1211670694 |
| Principal investigator 1 | Roche TCRC, Inc. | $589.50 | 10/23/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669946 |
| Principal investigator 1 | ABBVIE INC. | $625.00 | 10/22/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | a glogal real world evidence study on the long term effect of abbv-951 | No dispute reported | 06/30/2026 | 1202517707 |
| Principal investigator 1 | ABBVIE INC. | $625.00 | 10/22/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202518083 |
| Principal investigator 1 | ABBVIE INC. | $928.80 | 10/16/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202517177 |
| Principal investigator 1 | Roche TCRC, Inc. | $38,167.20 | 10/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669938 |
| Principal investigator 1 | ABBVIE INC. | $4,252.50 | 10/09/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202514593 |
| Principal investigator 1 | Roche TCRC, Inc. | $6,934.50 | 10/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669922 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,905.40 | 10/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669927 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,511.38 | 10/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669933 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,500.00 | 10/09/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669942 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $23,898.38 | 10/09/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046926 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $200.00 | 10/09/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046928 |
| Principal investigator 1 | Ipsen Innovation | $43.50 | 09/26/2025 | Non-covered Recipient Entity Usf Health Byrd Alzheimers Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288468 |
| Principal investigator 1 | Ipsen Innovation | $3,989.94 | 09/23/2025 | Non-covered Recipient Entity Usf Health Byrd Alzheimers Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288472 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,268.70 | 09/23/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046924 |
| Principal investigator 1 | Roche TCRC, Inc. | $4,218.00 | 09/11/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669911 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,402.69 | 09/11/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046922 |
| Principal investigator 1 | ABBVIE INC. | $6,952.50 | 09/04/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202509954 |
| Principal investigator 1 | Roche TCRC, Inc. | $775.68 | 08/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669889 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $909.23 | 08/26/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046920 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 08/21/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202505529 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,532.35 | 08/21/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046918 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,188.70 | 08/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669885 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,835.80 | 08/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669905 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,486.74 | 08/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669916 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,271.37 | 08/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669919 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,779.08 | 08/14/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046916 |
| Principal investigator 1 | ABBVIE INC. | $333.33 | 08/12/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202504287 |
| Principal investigator 1 | Ipsen Innovation | $3,952.37 | 08/08/2025 | Non-covered Recipient Entity Usf Health Byrd Alzheimers Institute | A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants | No dispute reported | 06/30/2026 | 1184288474 |
| Principal investigator 1 | ABBVIE INC. | $3,073.95 | 08/05/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202502144 |
| Principal investigator 1 | Roche TCRC, Inc. | $491.75 | 08/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669882 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,000.00 | 08/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669893 |
| Principal investigator 1 | Roche TCRC, Inc. | $703.00 | 08/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669897 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,277.15 | 07/31/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046914 |
| Principal investigator 1 | ABBVIE INC. | $1,285.20 | 07/17/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202498564 |
| Principal investigator 1 | ABBVIE INC. | $21,000.00 | 07/17/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202498570 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,268.70 | 07/17/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046912 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 07/08/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202497076 |
| Principal investigator 1 | ABBVIE INC. | $4,252.50 | 07/08/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202497078 |
| Principal investigator 1 | ABBVIE INC. | $8,200.00 | 07/08/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202497080 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $16,686.01 | 07/03/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046910 |
| Principal investigator 1 | ABBVIE INC. | $2,146.50 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202494377 |
| Principal investigator 1 | ABBVIE INC. | $11,815.00 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202494501 |
| Principal investigator 1 | ABBVIE INC. | $4,252.50 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202494503 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,500.00 | 06/24/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046900 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $172.80 | 06/24/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046902 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $737.10 | 06/24/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046904 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $114.75 | 06/24/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046906 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,132.00 | 06/24/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046908 |
| Principal investigator 1 | Roche TCRC, Inc. | $72,204.30 | 06/19/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669765 |
| Principal investigator 1 | Roche TCRC, Inc. | $408.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669783 |
| Principal investigator 1 | Roche TCRC, Inc. | $408.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669807 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,092.85 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669824 |
| Principal investigator 1 | Roche TCRC, Inc. | $476.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669829 |
| Principal investigator 1 | Roche TCRC, Inc. | $408.00 | 06/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669859 |
| Principal investigator 1 | ABBVIE INC. | $9,652.50 | 06/03/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202488777 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $889.00 | 06/01/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046898 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,186.69 | 05/28/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669865 |
| Principal investigator 1 | Roche TCRC, Inc. | $282.96 | 05/28/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669868 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $500.00 | 05/27/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046896 |
| Principal investigator 1 | Roche TCRC, Inc. | $23,992.00 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669745 |
| Principal investigator 1 | Roche TCRC, Inc. | $649.51 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669750 |
| Principal investigator 1 | Roche TCRC, Inc. | $288.60 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669756 |
| Principal investigator 1 | Roche TCRC, Inc. | $521.50 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669773 |
| Principal investigator 1 | Roche TCRC, Inc. | $818.86 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669779 |
| Principal investigator 1 | Roche TCRC, Inc. | $476.00 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669787 |
| Principal investigator 1 | Roche TCRC, Inc. | $3,241.63 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669792 |
| Principal investigator 1 | Roche TCRC, Inc. | $263.96 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669797 |
| Principal investigator 1 | Roche TCRC, Inc. | $2,184.32 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669802 |
| Principal investigator 1 | Roche TCRC, Inc. | $476.00 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669810 |
| Principal investigator 1 | Roche TCRC, Inc. | $340.00 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669815 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,200.71 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669818 |
| Principal investigator 1 | Roche TCRC, Inc. | $696.75 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669821 |
| Principal investigator 1 | Roche TCRC, Inc. | $589.50 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669842 |
| Principal investigator 1 | Roche TCRC, Inc. | $408.00 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669846 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,151.88 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669852 |
| Principal investigator 1 | Roche TCRC, Inc. | $681.00 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669855 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,472.10 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669863 |
| Principal investigator 1 | Roche TCRC, Inc. | $521.50 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669872 |
| Principal investigator 1 | Roche TCRC, Inc. | $612.00 | 05/22/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669878 |
| Principal investigator 1 | Genentech, Inc. | $253,280.00 | 05/16/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | No dispute reported | 06/30/2026 | 1211670641 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,750.00 | 05/08/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046890 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,650.00 | 05/08/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046892 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $12,500.00 | 05/08/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046894 |
| Principal investigator 1 | ABBVIE INC. | $7,526.25 | 05/07/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202483583 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,532.35 | 05/02/2025 | Non-covered Recipient Entity The University of South Florida | A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) | No dispute reported | 06/30/2026 | 1244046888 |
| Principal investigator 1 | Roche TCRC, Inc. | $136.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669759 |
| Principal investigator 1 | Roche TCRC, Inc. | $708.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669769 |
| Principal investigator 1 | Roche TCRC, Inc. | $544.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669776 |
| Principal investigator 1 | Roche TCRC, Inc. | $619.51 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669835 |
| Principal investigator 1 | Roche TCRC, Inc. | $1,043.00 | 04/24/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669838 |
| Principal investigator 1 | Genentech, Inc. | $4,373.60 | 04/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | No dispute reported | 06/30/2026 | 1211670649 |
| Principal investigator 1 | ABBVIE INC. | $6,565.50 | 04/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202474483 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 04/04/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202474486 |
| Principal investigator 1 | ABBVIE INC. | $16,700.00 | 04/03/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease | No dispute reported | 06/30/2026 | 1202470786 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) | No dispute reported | 06/30/2026 | 1202465425 |
| Principal investigator 1 | Roche TCRC, Inc. | $864.73 | 03/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669735 |
| Principal investigator 1 | ABBVIE INC. | $3,015.90 | 03/06/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202458054 |
| Principal investigator 1 | Roche TCRC, Inc. | $655.51 | 03/06/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669725 |
| Principal investigator 1 | Roche TCRC, Inc. | $702.75 | 03/06/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669728 |
| Principal investigator 1 | Roche TCRC, Inc. | $871.51 | 03/06/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669742 |
| Principal investigator 1 | ABBVIE INC. | $1,300.00 | 02/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202453422 |
| Principal investigator 1 | ABBVIE INC. | $4,750.00 | 02/20/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202453436 |
| Principal investigator 1 | Genentech, Inc. | $3,196.80 | 02/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | No dispute reported | 06/30/2026 | 1211670623 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 02/13/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) | No dispute reported | 06/30/2026 | 1202451853 |
| Principal investigator 1 | Sage Therapeutics, LLC | $1,458.33 | 02/12/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SAGE-718 IN PARKINSON'S DISEASE COGNITIVE IMPAIRMENT | No dispute reported | 06/30/2026 | 1206580851 |
| Principal investigator 1 | Roche TCRC, Inc. | $75,439.80 | 01/16/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669732 |
| Principal investigator 1 | Roche TCRC, Inc. | $645.09 | 01/16/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Phase II study in early stage Parkinson s Disease Patients | No dispute reported | 06/30/2026 | 1211669738 |
| Principal investigator 1 | Genentech, Inc. | $999.00 | 01/14/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA | A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease | No dispute reported | 06/30/2026 | 1211670633 |
| Principal investigator 1 | UCB SA | $57,541.82 | 01/13/2025 | Non-covered Recipient Entity UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER | A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease | No dispute reported | 06/30/2026 | 1246658330 |
| Principal investigator 1 | ABBVIE INC. | $1,285.20 | 01/09/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202437760 |
| Principal investigator 1 | UCB SA | $18,890.75 | 01/09/2025 | Non-covered Recipient Entity UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246656953 |
| Principal investigator 1 | ABBVIE INC. | $550.00 | 01/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES | Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) | No dispute reported | 06/30/2026 | 1202436500 |
| Principal investigator 1 | ABBVIE INC. | $438.75 | 01/02/2025 | Non-covered Recipient Entity UNIVERSITY OF SOUTH FLORIDA | M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease | No dispute reported | 06/30/2026 | 1202435693 |